Source: Seeking Alpha
Celgene Corporation (NASDAQ:CELG)
Q2 2014 Earnings Conference Call
July 24, 2014 9:00 am ET
Executives
Robert Hugin – Chairman, Chief Executive Officer
Jacqualyn Fouse – Executive Vice President, Chief Financial Officer
Mark Alles – Global Head, Hematology and Oncology
Scott Smith – Global Head, Inflammation and Immunology
Patrick Flanigan – Vice President, Investor Relations
Analysts
Josh Schimmer – Piper Jaffray
Geoffrey Porges – Sanford Bernstein
Terence Flynn – Goldman Sachs
Ian Somaiya – Nomura
Robyn Karnauskas – Deutsche Bank
Yaron Werber – Citi
Geoff Meacham – JP Morgan
Ravi Mehrotra – Credit Suisse
Mark Schoenbaum – ISI Group
Brian Abrahams – Wells Fargo Securities
Matt Roden – UBS
Michael Yee- RBC Capital Markets
Mara Goldstein – Cantor Fitzgerald
Thomas Wei – Jefferies
Howard Liang – Leerink Swann
Operator
Good morning and welcome to the Celgene Second Quarter 2014 Earnings conference call. All participants will be in a listen-only mode until the question and answer session at the end of the conference. I would like to remind you that this call is being recorded.
I would now like to turn the conference over to Patrick Flanigan, Vice President, Investor Relations at Celgene. Please go ahead.
Patrick Flanigan – Vice President, Investor Relations
Thanks, Nicole, and welcome everyone to our second quarter earnings conference call. The press release reporting our financial results in addition to the presentation for today’s webcast can be accessed by going to the Investor Relations section of the corporate website at www.celgene.com.
Joining me in the room today with prepared remarks are Bob Hugin, our Chairman and Chief Executive Officer; Jacquie Fouse, our Chief Financial Officer; Mark Alles, who is Global Head of our Hematology and Oncology franchise; and the Global Head of our Inflammation and Immunology franchise, Scott Smith.
Pages: First |1 | ... | Next → | Last | View Full Transcript